首页> 美国卫生研究院文献>Clinical Medicine Insights. Oncology >Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

【2h】

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

机译：甲磺酸依瑞布林作为第二或更多化疗方案的转移性乳腺癌患者的前瞻性分析：印度的经验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background:Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of eribulin monotherapy in heavily pretreated patients with MBC.

机译：背景：甲磺酸依瑞布林是一种非紫杉烷微管抑制剂，可在蒽环类和紫杉烷治疗后用于转移性乳腺癌（MBC）患者。这项研究的目的是调查在大量预处理的MBC患者中单药治疗eribulin的有效性和安全性。

著录项

期刊名称 Clinical Medicine Insights. Oncology
作者
BJ Srinivasa; Bhanu Prakash Lalkota; Girish Badarke; Diganta Hazarika; Nasiruddin Mohammad; Sulav Sapkota; Mansi Khanderia; D Tousif; Raghavendra Rao; Amritanshu Ram; Shekar Patil; Radheshyam Naik;
展开▼
作者单位

展开▼
年(卷),期 2018(12),-1
年度 2018
页码 1179554918782475
总页数 4
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Breast cancer eribulin mesylate progression-free survival overall survival cancer chemotherapy;

机译：乳腺癌;甲磺酸艾瑞布林;无进展生存期;总体生存期;癌症化疗;

相似文献

外文文献
中文文献
专利

1. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer [J] . Lee Schwartzberg, Kristi McIntyre, Sharon Wilks, BMC Cancer . 2019,第1期

机译：与局部复发或转移性乳腺癌接受一线二林蛋白甲磺酸盐的患者与局部复发或转移性乳腺癌的患者的健康有关的生活质量
2. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE [J] . Leo Silvana, Arnoldi Ermenegildo, Repetto Lazzaro, The oncologist . 2019,第6期

机译：Eribulin甲磺酸盐作为第三或后续的局部复发性或转移性乳腺癌患者的化疗：Gioger的多中心观察研究（意大利老年肿瘤学群） - 人
3. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE [J] . Silvana Leo, Giovanna Campanella, Mariangela Ciccarese, The oncologist . 2019,第6期

机译：Eribulin甲磺酸盐作为第三或后续的局部复发性或转移性乳腺癌患者的化疗：Gioger的多中心观察研究（意大利老年肿瘤学群） - 人
4. Correlations between depressive symptoms and quality of life in metastatic breast cancer patients during chemotherapy [C] . Dragomir B.I., Campean A. European Association of Psychosomatic Medicine., Annual Meeting. . 2014

机译：化疗期间转移性乳腺癌患者抑郁症状与生活质量的相关性
5. Effects of primary prophylaxis of neutropenia on outcomes, utilization and expenditures for elderly breast cancer patients receiving chemotherapy. [D] . Rajan, Suja S. 2009

机译：一级预防中性粒细胞减少对老年接受化疗的乳腺癌患者的结局，利用和支出的影响。
6. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer [O] . Lee Schwartzberg, Kristi McIntyre, Sharon Wilks, 2019

机译：接受一线甲磺酸艾瑞布林或曲妥珠单抗治疗局部复发或转移性乳腺癌的患者的健康相关生活质量
7. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer [O] . Lee Schwartzberg, Kristi McIntyre, Sharon Wilks, 2019

机译：与局部复发或转移性乳腺癌接受一线二林蛋白甲磺酸盐的患者与局部复发或转移性乳腺癌的患者的健康有关的生活质量

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅